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Mitochondria represent major sources of basal reactive oxygen species (ROS) production
of the cardiomyocyte. The role of ROS as signaling molecules that mediate different
intracellular pathways has gained increasing interest among physiologists in the last
years. In our lab, we have been studying the participation of mitochondrial ROS in the
intracellular pathways triggered by the renin-angiotensin II-aldosterone system (RAAS)
in the myocardium during the past few years. We have demonstrated that acute
activation of cardiac RAAS induces mitochondrial ATP-dependent potassium channel
(mitoKATP) opening with the consequent enhanced production of mitochondrial ROS.
These oxidant molecules, in turn, activate membrane transporters, as sodium/hydrogen
exchanger (NHE-1) and sodium/bicarbonate cotransporter (NBC) via the stimulation of the
ROS-sensitive MAPK cascade. The stimulation of such effectors leads to an increase
in cardiac contractility. In addition, it is feasible to suggest that a sustained enhanced
production of mitochondrial ROS induced by chronic cardiac RAAS, and hence, chronic
NHE-1 and NBC stimulation, would also result in the development of cardiac hypertrophy.
Keywords: cardiac myocyte, second messenger systems, sodium-hydrogen antiporter, sodium-bicarbonate
symporters, reactive oxygen species
INTRODUCTION
The renin-angiotensin-aldosterone-system (RAAS) represents
one of the main endocrine systems that regulate cardiac physi-
ology. At present, it is well recognized that angiotensin II (Ang II)
is produced and secreted locally in several tissues, including the
heart (Husain et al., 1994). Sadoshima’s group has shown that
the hormone is secreted from intracellular vacuoles in response to
myocyte stretching for the first time. This Ang II exerts autocrine
and paracrine effects, leading to cardiac hypertrophy (Sadoshima
et al., 1993; Sadoshima and Izumo, 1996). Cingolani’s group
conducted an in depth study of this autocrine pathway as a physi-
ological mechanism responsible for the slow force response (SFR)
to myocardial stretch (Cingolani et al., 2001, 2003) and showed
the similarities of both the physiological and pathological path-
ways (Cingolani et al., 2008). The critical role played by the
cardiac Na+/H+ exchanger (NHE-1) activation in both physi-
ological and pathological responses was demonstrated not only
pharmacologically with NHE-1 inhibitors (Cingolani et al., 2011)
but also by specific NHE-1 silencing following direct intramy-
ocardial injection of small interfering RNA into rat left ven-
tricular wall (Morgan et al., 2011; Cingolani et al., 2013). The
precise mechanism to explain pathological responses is unclear
and warrants further investigation. However, it is possible that
the time of exposure to the stimulus and the amount of ROS
produced could be important in determining the physiological
or pathological pathways. Increasing time and amount of ROS
exposure could exert a differential impact in calcium handling,
an initial acute response leading to inotropic effects followed
by a sustained response that could involve calcium-activated
targets that participate in cardiac hypertrophy or heart failure,
like calcineurin, or Ca2+-calmodulin-dependent kinase type II
(CaMKII).
Although still somewhat controversial (Silvestre et al., 1998,
1999; Takeda et al., 2000; Gomez-Sanchez et al., 2004; Chai and
Danser, 2006), it has been suggested that aldosterone synthase
exists in the myocyte (Silvestre et al., 1998, 1999; Takeda et al.,
2000), supporting the presence of a local RAAS (Varagic and
Frohlich, 2002). Furthermore, the link between Ang II or its
AT1 receptor, and the mineralocorticoid receptor (MR) is an
accepted fact (Lemarie et al., 2008; Grossmann and Gekle, 2009).
Consistently, it has also been described that some physiological
cardiac effects of Ang II, as the SFR, can be prevented in the
presence of MR blockers (Caldiz et al., 2011).
Although the idea that mitochondria are the main sources
of basal reactive oxygen species (ROS) in other mammalian
cells has been recently challenged, (Brown and Borutaite, 2012)
their role as a very important source of ROS in the heart has
been widely accepted. Mitochondrial superoxide anion (O2−)
and its product, hydrogen peroxide (H2O2), were demonstrated
to be important molecules implicated in several cardiac func-
tions usually acting as second signal molecules of RAAS (Kimura
et al., 2005a,b; Caldiz et al., 2007, 2011; De Giusti et al., 2008,
2009).
In this review, we will briefly summarize the current knowl-
edge about the involvement of mitochondrial ROS as media-
tors of the signaling pathways triggered by RAAS in cardiac
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myocytes without stressing out if they participate in acute or
chronic signals. We will discuss the participation of the different
components of RAAS in ROS production and in cardiac signaling
leading to physiological and pathological responses. Particularly,
we will remark the implication of the ion transporters (NHE-1
and NBC) in sodium and calcium overload and its relation with
ROS signaling.
ANGIOTENSIN II, ENDOTHELIN-1, ALDOSTERONE AND
EPIDERMAL GROWTH FACTOR: INDEPENDENT SIGNALS OR
DIFFERENT COMPONENTS OF THE SAME CARDIAC
SYSTEM?
Ang II is involved in the regulation of almost all cardiac functions.
At present, it is well known that Ang II stimulates membrane ions
transporters as NHE-1 (Fliegel and Karmazyn, 2004; Cingolani
et al., 2005) and Na+/HCO3− cotransporter (NBC) (Baetz et al.,
2002; De Giusti et al., 2009; Aiello and De Giusti, 2012). These
regulations are crucial for the correct electrical and mechanical
cardiac functions. On the other hand, it is important to keep in
mind that when RAAS is chronically active it is responsible for
several cardiac diseases, for example, hypertrophy, heart failure
and electrical disturbances (Domenighetti et al., 2007; Fischer
et al., 2007; Mehta and Griendling, 2007; Palomeque et al., 2009;
Li et al., 2013).
The mechanism of how the activation of NHE-1 or NBC
regulates cardiac contractility seems to involve the increase in
intracellular Na+ concentration ([Na+]i) (Vaughan-Jones et al.,
2006) due to the activation of these transporters and the subse-
quent increase in intracellular calcium concentration ([Ca2+]i)
due to the activation of the reverse mode of the Na+/Ca2+
exchanger (NCX) (Perez et al., 2001; Rothstein et al., 2002; Bril,
2003; Morgan et al., 2011). Interestingly, the same pathway is pro-
posed to explain the development of cardiac hypertrophy (Ennis
et al., 2007; Cingolani et al., 2008).
In addition, endothelin-1 (ET-1) and aldosterone (Ald) are
key modulators of cardiac physiology per se. We have shown
that ET-1 activates the NHE-1 (Aiello et al., 2005; De Giusti
et al., 2008) leading to a positive inotropic effect (Szokodi et al.,
2008). Moreover, Ald has been shown to activate NHE-1, (De
Giusti et al., 2011) increase NHE-1 expression (Karmazyn et al.,
2003) and induce left ventricular hypertrophy independently
from its classical effects on regulation of renal Na+ excretion
and blood pressure (Qin et al., 2003; Yoshida et al., 2005; Diez,
2008). Classically, Ald enters the cells and binds to the MR
located mainly in the cytosol. This binding translocates the MR
to the nucleus, where it acts as a ligand-induced transcrip-
tion factor. However, evidence has been presented that acti-
vated MR can elicit additional non-classical effects, which do
not require transcription or translation of genes (Ebata et al.,
1999; Mihailidou et al., 2004; Chai et al., 2005; Grossmann
and Gekle, 2009). In addition, several of these rapid non-
genomic effects of Ald involves the transactivation of the epi-
dermal growth factor receptor (EGFR) (Grossmann and Gekle,
2007; Grossmann et al., 2007), which can, in turn, stimulate
the NHE-1 (De Giusti et al., 2011). Moreover, it was reported
that at least a small fraction of the classic MR is located in the
cell plasma membrane where it is co-localized with the EGFR,
inducing the transactivation of the latter (Grossmann et al.,
2010).
More recently, it was demonstrated that certain non-genomic
effects of Ald in vascular smooth muscle were due to simultane-
ous activation of MR and a surface membrane G protein–coupled
receptor, the GPR30 (Gros et al., 2011, 2013). In agreement, grow-
ing evidence is appearing which demonstrate that GPR30 could
be another Ald receptor involved in the rapid effects of the hor-
mone in the cardiovascular system (Gros et al., 2011; Meyer et al.,
2011).
At present, it is accepted that many effects initially believed
to be mediated by Ang II, as the positive inotropic effect
(PIE), and the increase in the SFR after myocardial stretch-
ing, are in fact attributable to the action of ET-1, which is
released by Ang II (Perez et al., 2003; Cingolani et al., 2006,
2008; Villa-Abrille et al., 2006). Moreover, Ald appears to medi-
ate some Ang II effects that participate in the same pathway
of Ang II and ET-1 (Figure 1) (Xiao et al., 2004; Lemarie
et al., 2008; Caldiz et al., 2011). Recently, it has been demon-
strated that EGF is also implicated in cardiac physiology (De
Giusti et al., 2011), and it has been described that the trans-
activation of the EGF receptor (EGFR) is involved in some
RAAS effects (Shah and Catt, 2003; Zhai et al., 2006; De Giusti
et al., 2011). We have suggested that all these extracellular and
intracellular stimuli are pieces of the same signaling pathway
(Figure 1). In this scenario, the activation of the MR takes
place downstream from the Ang II/ET-1 receptors and upstream
of the EGFR. The activation of EGFR triggers the intracel-
lular ROS production, which leads to the stimulation of dif-
ferent kinases that finally activate the NHE-1 (Caldiz et al.,
2011).
Interestingly, almost all the effects of these hormones involve
ROS-mediated pathways (Zhang et al., 2001; Caldiz et al., 2007,
2011; Bartosz, 2009). In this regard, it is accepted that Ang II,
(Giordano, 2005; Kimura et al., 2005b; De Giusti et al., 2009),
ET-1 (De Giusti et al., 2008; Kubin et al., 2011), Ald (Hayashi
et al., 2008; Caldiz et al., 2011) and EGF (De Giusti et al., 2011)
can activate NADPH oxidase (NOX), which then, as further
explained below, can stimulate mitochondrial ROS production
and mediate the effects of such hormones (Figure 1). Therefore,
it seems clear that RAAS effects are in close relationship with ROS
generation, and in order to be able to modulate RAAS signal-
ing, we should investigate the regulation of ROS production in
detail.
MAJOR SOURCES OF ROS: NOX, MITOCHONDRIA AND
THEIR CROSS-TALK
ROS have been considered deleterious agents for a long time.
However, in the last years, evidence has emerged supporting
their role as second messengers (D’autreaux and Toledano, 2007).
Under physiological conditions, the production of ROS is highly
restricted to specific subcellular sites. The major sources of ROS
in the cardiomyocytes are NOX (Bedard and Krause, 2007) and
the I, II and III complexes of the mitochondrial respiratory
chain (Camara et al., 2010; Dedkova et al., 2013; Drose, 2013;
Li et al., 2013; Wojtovich et al., 2013). In this regard, com-
plex II is emerging as the major modulator of mitochondrial
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FIGURE 1 | ROS-induced ROS-release mechanism triggered by RAAS.
Scheme representing the sequential steps involved in the production of
mitochondrial ROS after the initial Ang II stimulation. Ang II acting on AT1
receptors induces the release of intracellular ET-1, which, in turn, acts in an
autocrine manner on ETA receptors. This autocrine action leads to the
activation of the mineralocorticoid receptor (MR), which induces the
transactivation of the EGFR, possibly via the release of membrane
heparin-bound EGF (HB-EGF). The stimulation of the EGFR leads to the
activation of the NADPH oxidase (NOX), which produces superoxide anion
(O2−) and quickly dismutate by superoxide dismutase (SOD) to hydrogen
peroxide (H2O2). This permanent and stable oxidant molecule produces the
opening of mitochondrial ATP-dependant potassium channels (mitoKATP) with
the subsequent enhanced production of mitochondrial O2− by the electron
transport chain (mainly by complex II). These mitochondrial ROS are released
to the cytosol (ROS-induced ROS-release mechanism), where they stimulate
redox sensitive MAPkinases ERK 1/2 and p90RSK, which, in turn, activate
NHE-1 and NBC, pH regulation transporters that induce the increase in
intracellular Na+. Finally, this cytosolic Na+ increase favors the operation of
the reverse mode of NCX, promoting the influx of Ca2+ into the cell. The
enhancement of intracellular Ca2+ in the cardiomyocyte could lead to a
positive inotropic effect in the short term and/or the development of cardiac
hypertrophy in a time-prolonged scenario.
ROS production (Drose, 2013). Moreover, it was proposed that
complex II can adopt different roles as a producer or modu-
lator of mitochondrial ROS, depending on the substrate sup-
ply and the activities of the other respiratory chain complexes
(Drose, 2013). The primary function of complex II is to maintain
the reduced state of mitochondrial chain complexes (Wojtovich
et al., 2013). Importantly, it was demonstrated that complex II,
instead of complex I or III, is the major source of ROS during
heart failure (Dedkova et al., 2013). On the other hand, it has
been proposed that the production of “deleterious ROS” dur-
ing reperfusion can be related to complex I, while the generation
of “signaling ROS” during preconditioning occurs at complex
II (Drose, 2013). Although the precise mechanism is not clear
yet, the modulation of complex II seems to be cardioprotec-
tive during ischemic preconditioning (Wojtovich et al., 2013).
These data, however, do not support previous results which
suggested that the production of ROS induced after mitoKATP
opening is accounted by complex I (Andrukhiv et al., 2006),
and that ischemic preconditioning is mediated by ROS gener-
ated after the activation of these channels (Oldenburg et al.,
2004).
At present it is accepted that NOX produce extracellular
O2−, which dismutate to H2O2. Although it has been generally
assumed that H2O2 diffuses back into the cell across the plasma
membrane, recent evidence suggests that it might preferen-
tially enter the cell through specific aquaporin channels (Bienert
et al., 2007; Miller et al., 2010), providing a potential mecha-
nism through which ROS signaling could be regulated. It is also
accepted that matrix H2O2 permeates through the mitochon-
drial inner membrane after being produced by the action of
Mn-SOD, which dismutates mitochondrial O2−. However, it is
important to note that O2− also permeates mitochondrial mem-
brane through anion channels (Bedard and Krause, 2007) and
hence could potentially act as a signaling molecule. The SFR,
which represents an acute and physiological response triggered
by RAAS activation, was reported to be due to H2O2 signaling
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(Caldiz et al., 2007). Moreover, experiments by Sabri et al. (1998)
and Rothstein et al. (2002) indicated that H2O2 is the intracellular
signal leading to the activation of kinases that phosphorylate the
NHE-1. On the other hand, O2−- not H2O2- was reported to be
the signaling molecule in the ET-1-induced stimulation of cardiac
L-type calcium channels (Zeng et al., 2008). Nevertheless, if mito-
chondrial H2O2 or O2− could cause different responses to RAAS
activation, i.e., acute versus chronic, it would be an interesting
topic that deserves future investigation.
NOX and mitochondria are not totally independent sources
of ROS, since recent evidence demonstrate the existence of a
substantial interplay between both sources, such as activation of
one leading to the activation of the other (Dikalov, 2011). In
2000, Zorov et al. (2000) published the first study describing
the phenomenon called “ROS-induced ROS-release” by which
a small amount of ROS triggers greater ROS production from
the mitochondria. Five years later, Dr. Kimura’s group proposed
the Ang II-induced NOX stimulation as the generator of the
small amount of ROS triggering mitochondrial ROS production
(Kimura et al., 2005a) (Figure 1). It is important to note that
this “ROS-induced ROS-release” mechanism is implicated in Ang
II-mediated preconditioning.
The main link between both sources of ROS seems to be the
mitochondrial ATP-dependent potassium channel (mitoKATP).
It was demonstrated that the opening of these channels is cru-
cial to stimulate ROS production by the respiratory chain. Three
phenomena were proposed to activate the mitochondrial respira-
tory chain and produce ROS: moderate matrix swelling, matrix
alkalinization and inner membrane depolarization (Pain et al.,
2000; Andrukhiv et al., 2006). A still unresolved issue is how the
mitoKATP are opened. On the one hand, it has been reported
that O2− can directly stimulate the mitoKATP, (Zhang et al., 2001,
2007) on the other hand, there is enough evidence that demon-
strate the involvement of PKC as an activator of mitoKATP (Sato
et al., 1998; Costa et al., 2006; Costa and Garlid, 2008). In addi-
tion, other studies have proposed that the cardioprotective effect
of Gi-coupled receptor agonists are due to EGFR transactivation
and subsequent stimulation of the PI3K/Akt pathway, which lead
to a PKG-mediated opening of mKATP channels and increased
O2− production (Krieg et al., 2002, 2003, 2004). These authors
proposed that PI3K/Akt increase nitric oxide levels, which, in
turn, stimulates the guanylate cyclase, augmenting cGMP content
and activating PKG, inducing the opening of mitoKATP channels
(Krieg et al., 2004; Oldenburg et al., 2004).
Interestingly, it seems that not only NOX-derived ROS trigger
mitochondrial ROS production, but also a small amount of mito-
chondrial ROS released to the cytosol could potentially further
activate ROS-induced ROS-release in neighboring mitochondria
(Costa and Garlid, 2008). In addition, mitochondrial ROS can
stimulate NOX directly or mediated by PKC activation (Doughan
et al., 2008; Wenzel et al., 2008; Camara et al., 2010; Dikalov,
2011). These different signaling regulations create a truly cross-
talk between the major sources of ROS (Daiber, 2010). This issue
is important because it converts the mitochondrion to a ROS-
amplifier. Myocytes spend little energy to start the intracellular
signaling and then the cycle helps to potentiate ROS-production
(Figure 2).
THE MITOCHONDRIAL ROS ARE THE MEDIATORS OF RAAS-
INDUCED NHE-1 AND NBC REGULATION, OR IS IT THE
OPPOSITE?
ROS-mediated activation of NHE-1 (Sabri et al., 1998; Snabaitis
et al., 2002; Caldiz et al., 2007, 2011; De Giusti et al., 2008) and
NBC (De Giusti et al., 2009; Aiello and De Giusti, 2012) has been
reported to be due to redox sensitive kinase-mediated phospho-
rylation. In this regard, there is enough evidence supporting the
notion that ROS favors the activation of ERK 1/2 and p90RSK in
neonatal and adult cardiomyocytes (Sabri et al., 1998; Rothstein
et al., 2002).
As described above, the components of RAAS are well known
activators of ROS production (Hanna et al., 2002; Seshiah et al.,
2002; Kimura et al., 2005b; Doughan et al., 2008). Moreover, in
our lab, we have investigated the pathway by which myocardial
stretch sequentially stimulates ROS production, activates ERK 1/2
and p90RSK and finally leads to the stimulation of NHE-1 (Caldiz
et al., 2007, 2011; Villa-Abrille et al., 2010). We demonstrated
that NHE-1 stimulation is responsible for the SFR in the acute
phase. Thus, we proposed that NHE-1 stimulation is potentially
responsible, in a more prolonged term, for chronic and patholog-
ical responses, such as the development of cardiac hypertrophy
(Cingolani et al., 2008).
As Figure 1 shows, RAAS signaling leads to an increase in ROS
production and subsequent activation of ERK 1/2 and p90RSK
kinases, which stimulate both transporters, NHE-1 and NBC. The
stimulation of these transporters might lead to an increase in
[Na+]i (Vaughan-Jones et al., 2006), which is known to induce
the operation of the reverse mode of NCX, leading to an increase
in [Ca2+]i and a positive inotropic effect. Mitochondrial Ca2+
(mCa2+) uptake through the calcium uniporter (CaU) is in
part dependent on the Ca2+ gradient between the cytosol and
the mitochondrial matrix (Camara et al., 2010). Thus, it seems
evident that the cytosolic Ca2+ increase, following the activa-
tion of NHE-1 and NBC, may lead to an increase in mCa2+.
Mitochondrial Ca2+ loading regulates cellular respiration and
mediates cell death (Camara et al., 2010). Calcium, through the
activation of the CaMKII, was described as one of the main
activators of NOX (Nishio et al., 2012) and mitochondrial ROS
production (Song et al., 2011), creating a positive feed-back (feed-
back 3, Figure 2) by which the ROS pathways acquire a central
role in cell physiology (Trebak et al., 2010; Gul et al., 2012).
It has been described that the NHE-1 blockers attenuate the
mCa2+ overload, ROS production and mPTP opening induced
by ouabain (Toda et al., 2007). These authors proposed two pos-
sible mechanisms: (a) the NHE-1 inhibition prevents the increase
in [Na+]i and subsequent [Ca2+]i, which reduces the driving
force for mCa2+ uptake, and (b) NHE-1 inhibition might indi-
rectly activate the mitoKATP channel (the protection induced
by NHE-1 blockers is prevented with the mitoKATP blocker 5-
HD). In addition, it has been demonstrated that NHE-1 inhi-
bition prevents mPTP opening during the first minutes after
reperfusion, leading to an improvement of mitochondrial func-
tion as well as an attenuation of pro-apoptotic factors. In this
work, the authors discussed several possibilities for the NHE-
1-inhibition-induced protection, being the most important the
attenuation of [Ca2+]i overload and the delay of pHi recovery
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FIGURE 2 | Potential sites of positive feedback mechanisms involved in
the mitochondrial ROS production during the activation of RAAS. The
H2O2 released by the mitochondria during the ROS-induced ROS-release
mechanism could activate NOX (possibly via CaMKII or PKC activation),
cycling the mitochondrial ROS production (positive feedback 1). The
mitochondrial ROS could also help to maintain the opening of mitoKATP
(positive feedback 2), perhaps through the activation of PKC. Finally, the
intracellular Ca2+ augmentation after NHE-1 and NCX reverse mode
stimulation could induce mitochondrial Ca2+ load and further ROS production
(positive feedback 3).
during reperfusion (Javadov et al., 2008). Moreover, Garciarena
et al. (2008) working on isolated mitochondria, showed that the
NHE-1 inhibitors modulate mitochondrial ROS production via a
direct mitochondrial action. However, the site of action has not
been elucidated. Nevertheless, it is important to point out again
that the careful regulation of ROS production, which involves the
modulation of calcium handling, represents a crucial process in
myocardial intracellular signaling (Figure 2).
MITOCHONDRIAL ROS AND CARDIAC PATHOLOGY
When the cells are exposed to the same stimuli for long periods of
time, they begin to lose their equilibrium, and in this scenario
ROS and Ca2+ might represent dangerous molecules, leading
to arrhythmias and cardiac hypertrophy (Terentyev et al., 2008;
Zhao et al., 2011; Maulik and Kumar, 2012). In this regard, high
mCa2+ impairs ATP synthesis leading to a loss in ion homeosta-
sis, opening of mPTP and matrix swelling. The irreversible mPTP
opening is associated with release of cytochrome C andmore ROS
production, resulting in a harmful vicious cycle of further ampli-
fication of ROS production, mCa2+ overload and irreversible cell
damage, which lead to cell death (Camara et al., 2010). On the
other hand, several investigations have demonstrated that a low
increase in matrix ROS is sufficient to trigger brief, stochastic
openings of mPTP, perhaps through reversible thiol oxidation
(Wang et al., 2008). Moreover, these transient brief openings of
mPTP have been involved as a “physiological valve”, alleviating
mCa2+ overload and providing protection against cellular injury
(Smaili and Russell, 1999; Kindler et al., 2003).
There are several evidences that involve the participation of
ROS produced by NOX in different models of heart failure with
RAAS activation (Sorescu and Griendling, 2002; Guo et al., 2006).
Since NOX-produced ROS can be amplified by ROS generated by
mitochondria during the ROS-induced-ROS release mechanism,
this process could be also involved in the development of car-
diac hypertrophy and the transition to heart failure. Indeed, it was
reported that mice that overexpress catalase (antioxidant enzyme
that degrades H2O2) targeted tomitochondria are resistant to car-
diac hypertrophy, fibrosis and mitochondrial damage induced by
Ang II as well as heart failure induced by overexpression of Gαq
(Dai et al., 2011). In addition, Ang II-inducedmitochondrial ROS
are implicated in the development of apoptosis (Choudhary et al.,
2008). Thus, breaking the ROS vicious cycle within mitochon-
dria by antioxidants specifically targeted to this organelle would
be effective to attenuate both cardiac hypertrophy and failure.
It was recently demonstrated that Ang II binds to AT1 and
AT2 receptors localized in the mitochondrial inner membrane
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(mAT1 and mAT2) (Abadir et al., 2011). The authors of
this study proposed an interesting model, where they asso-
ciated the subtype of Ang II receptor and the type of ROS
generated by mitochondria. In young animals, the activation
of mAT2 induced protective mitochondrial NO generation.
However, this protection disappeared with aging, possibly, due
to harmful ROS producing an increased expression of mAT1.
A similar speculation of mAT1 and mAT2 remodeling with
aging could be done for cardiovascular diseases. In contrast,
Doughan et al. (2008) demonstrated that Ang II does not
exert any effect on isolated mitochondria. Moreover, it will be
necessary to elucidate how Ang II gains access to the intra-
cellular space, either by internalization or by local synthe-
sis (Inagami, 2011). The relevance of this intracellular action
of Ang II on mitochondrial ROS production remains to be
studied.
FINAL NOTES AND PERSPECTIVES
The main objective of this review was to emphasize the participa-
tion of mitochondria in the signaling pathways of RAAS. As we
have shown, almost all the effects of RAAS involve the production
of ROS, and the main source of them appears to be mitochon-
dria. In summary, we attempted to call attention to the central
role of cardiomyocyte mitochondria as the sites where the cellular
signaling mediated by ROS converge.
Mitochondria have been mainly thought as the organelles that
generate energy. However, in the last years, we have learned that
mitochondria are much more than only an “ATP-plant produc-
tion”. They are involved in cellular ion homeostasis, oxidative
stress and cell survival or death. The main role of mitochondria
seems to be the supervisor of cell functions. Mitochondria are the
main source of ROS and, more important, they can interact with
others sources of ROS in order to amplify the signal. Moreover,
ROS regulate calcium signaling, which can also act as secondmes-
senger and further stimulate ROS production, creating a cycle,
capable of being regulated at many steps (Figure 2).
As commented above, in the past ROSwere thought exclusively
as deleterious molecules. However, recent studies show that they
appear to be very important second messengers that mediate dif-
ferent intracellular pathways. What has changed? The molecules,
the stimuli and the sources are the same. Perhaps, we should
believe that we are just beginning to uncover how the cells can
use harmful reactive species for their own benefit.
Finally, we would like to highlight that mitochondrial ROS
signaling may be an attractive target for therapeutic drugs in
order to suppress RAAS signals. However, due to the complexity
of the mechanisms involved, this idea requires careful evalua-
tion, since targeting the wrong site at the wrong moment could
not only worsen the disease, but could also suppress important
physiological signaling pathways.
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